Open in interactive viewer → charts, metric popovers & call review

HeartFlow's Best Quarter Ever, Priced Like a Warning

Revenue up 57%, a third straight quarter of acceleration, and a raised guide — yet the stock sits 20% below its late-October high. The market already paid for the data; now it wants the conversion.
HTFL · Earnings Call · 2026-11-12

A 57% quarter the tape won't pay for

HeartFlow's third quarter was the best momentum the company has shown: total revenue of $72.9 million, up 57% year over year, U.S. revenue up 60%, global cases up 89.5%, and a $15 million midpoint raise to full-year guidance of $262–264 million. “For the third consecutive quarter, our year-over-year revenue growth accelerated” — John Farquhar, President and Chief Executive Officer · 2026-11-12, John Farquhar said — a genuinely unusual shape for a medtech name at this scale, where growth curves normally bend the other way. The operating model is bending with it. Non-GAAP gross margin hit 83.8% versus 76.8% a year ago, total non-GAAP operating expenses fell to 90.7% of revenue from 100.9%, and the non-GAAP operating loss more than halved to $5 million from $11.1 million. The last filed quarter (period ended July 31) already showed 83.0% gross margin, a jump of 7.5 points year over year, with the operating margin still negative but improving by 14 points across two years. GAAP lags; the direction does not. And yet the tape disagrees. HTFL peaked at $60.53 on October 29 — right around TCT — and trades roughly 20% below that despite the raise. The setup is classic: the clinical data drop (P4 at TCT, DECIDE at AHA) front-ran the print, the stock priced the news, and the report itself had to fight a de-rating rather than ride a bid. The question the market is now asking isn't whether the evidence exists. It's how fast 11% penetration of the noninvasive testing market converts into dollars.

Plaque: compressing eight years into two

The single most consequential number on the call wasn't revenue. It was account velocity:

It took us 8 years to get to 1,000 on FFRCT. We'll get to 1,300 on Plaque in 2.

John Farquhar, President and Chief Executive Officer · 2026-11-12
That target has moved every quarter — 1,250 by year-end on the August call, 1,300 now — and payer coverage moved with it, from roughly 78% of U.S. lives last quarter to 82%, with more than 500 Plaque-enabled accounts entering 2026 versus 1,300 entering 2027. Just as important is the denominator: Plaque Analysis applies to about 60% of CCTAs versus roughly 33% for FFRCT, so every account that converts structurally raises revenue per scan. The early utilization path is the FFRCT 40–70% stenosis band as a beachhead, then expansion into 1–40% disease burden as referring physicians see LDL responses come back. Notably, management still refuses to call that a step change — last quarter it said utilization was “ahead of expectation. It's still nowhere near 60%” — John Farquhar, President and Chief Executive Officer · 2026-08-13, and that framing held. The DECIDE one-year outcomes are the proof-of-value that payer conversations need: 34% fewer major CVD events and roughly half the rate of heart attack versus CCTA alone, with LDL target attainment at 50% versus 35%. That is the first prospective outcomes data for any plaque tool — the differentiator that turns this from a features race into a guideline story.

From the scanner to the cath lab, then upstream

Two company-unique keywords now sit at the very top of HeartFlow's lexical table: PCI planning and high-risk asymptomatic. Neither is sector boilerplate; both are new architecture. The first is Navigator. P4, the only randomized trial of CT-guided PCI planning, met its primary endpoint — matching IVUS-guided planning on one-year target vessel failure while cutting median procedure time 27% and contrast use ~12% — and published simultaneously in the New England Journal of Medicine. The NAVIGATE-PCI registry showed Navigator changed the procedural plan in roughly 70% of patients. Add the Boston Scientific collaboration announced at TCT and you have “the only PCI planning tool backed by prospectively validated accuracy and RCT level data” — John Farquhar, President and Chief Executive Officer · 2026-11-12. It stays unreimbursed — same as management told us in August — but its job is strategic: making interventional cardiologists advocates for the CT-first pathway, with broader rollout staged for 2027. The second is the third wave. Three RCTs in high-risk asymptomatic populations — REFINE-CAC (~$3B), REWRITE-CAD (~$1B) enrolling in Q4 2026, and Evolve Plaque with Amgen (~$2B) in Q1 2027 — push total U.S. addressable market to roughly $11 billion. “We're going to expect to begin reporting out data by the end of 2028, and we'll enter these markets before the end of the decade” — John Farquhar, President and Chief Executive Officer · 2026-11-12 — a subtle slip from August's "before 2030," and the tell that this is a 2029+ revenue line, not a 2027 one. It also needs no new FDA clearance; the entire bet rides on expanding the existing Plaque LCD. Elegant and capital-efficient, but a single-payer-path dependency. That is precisely the theme the broader diagnostics cohort is shouting about. Across this week's reporters, coverage language dominates: one device name touted Medicare reimbursement secured, another a clear path to Medicare coverage, and globally the site of service and outcome-based pricing clusters keep advancing. HeartFlow's bull case is the same trade — reimbursement de-risking — wearing a coronary hat.

The words that vanished, and the price that didn't

What management stopped saying is as interesting as what it started. Plaque Staging, a top-five keyword last quarter, fell out of the top thirty entirely. So did autonomous processing — even though Vikram Verghese credited that initiative, in Q&A, as a driver of the margin expansion. "Lesion" and "breadth" are the company's two largest momentum decliners this cycle. The narrative has rotated from feature differentiation (staging, tracker, lesioned precision) toward trials, TAM and the HeartFlow AI platform as a new standard of care. That is a maturing-in-public shift, and it explains why a feature-rich quarter reads as an evidence quarter. Price is the other quiet lever. The company now expects Q1 2027 Plaque pricing “a little north of 10% versus consensus where consensus is today” — Vikram Verghese, Chief Financial Officer · 2026-11-12, with FFRCT ASP trends moderating from 2027 as the mix matures. In August the same message was unquantified — pricing would “step up more meaningfully in early '27” — Vikram Verghese, Chief Financial Officer · 2026-08-13. Quantifying it is a confidence signal; it is also the last easy price lever before volume has to carry the model. And the model needs carrying: management reiterated cash flow profitability by mid-2028 with $253 million of cash, while R&D intensity runs near 40% of revenue. That is the tension in one number: the trials that create the $6 billion third wave are the same trials that delay the profit. Which is why the most quotable line of the call was a warning, not a boast. On Plaque utilization: “I don't believe anything in this business is a hockey stick” — John Farquhar, President and Chief Executive Officer · 2026-11-12. A hockey stick entered the company's keyword set this quarter as a denial, not a promise. The quarter was exceptional; the guidance philosophy behind it is deliberately boring. In a name 20% off its high after a 57% growth print, that gap between execution and expectation is the whole investment case.